DE69719755T2 - Polymorphe verbindungen - Google Patents

Polymorphe verbindungen

Info

Publication number
DE69719755T2
DE69719755T2 DE69719755T DE69719755T DE69719755T2 DE 69719755 T2 DE69719755 T2 DE 69719755T2 DE 69719755 T DE69719755 T DE 69719755T DE 69719755 T DE69719755 T DE 69719755T DE 69719755 T2 DE69719755 T2 DE 69719755T2
Authority
DE
Germany
Prior art keywords
fluvastatin sodium
sodium
fluvastatin
water
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69719755T
Other languages
German (de)
English (en)
Other versions
DE69719755D1 (de
Inventor
Karol Horvath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9602477A external-priority patent/SE9602477D0/xx
Priority claimed from SE9700751A external-priority patent/SE9700751D0/xx
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Publication of DE69719755D1 publication Critical patent/DE69719755D1/de
Application granted granted Critical
Publication of DE69719755T2 publication Critical patent/DE69719755T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69719755T 1996-06-24 1997-06-18 Polymorphe verbindungen Expired - Lifetime DE69719755T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9602477A SE9602477D0 (sv) 1996-06-24 1996-06-24 Polymorphic compounds
SE9700751A SE9700751D0 (sv) 1997-03-03 1997-03-03 Polymorphic compounds
PCT/SE1997/001097 WO1997049681A1 (en) 1996-06-24 1997-06-18 Polymorphic compounds

Publications (2)

Publication Number Publication Date
DE69719755D1 DE69719755D1 (de) 2003-04-17
DE69719755T2 true DE69719755T2 (de) 2003-11-20

Family

ID=26662685

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69719755T Expired - Lifetime DE69719755T2 (de) 1996-06-24 1997-06-18 Polymorphe verbindungen

Country Status (11)

Country Link
US (1) US6124340A (enExample)
EP (1) EP0907639B1 (enExample)
JP (2) JP4282092B2 (enExample)
AT (1) ATE234282T1 (enExample)
AU (1) AU3366297A (enExample)
CY (1) CY2461B1 (enExample)
DE (1) DE69719755T2 (enExample)
DK (1) DK0907639T3 (enExample)
ES (1) ES2194202T3 (enExample)
PT (1) PT907639E (enExample)
WO (1) WO1997049681A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902202D0 (sv) 1999-06-10 1999-06-10 Astra Ab Production of aggregates
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
JP2004513112A (ja) * 2000-10-31 2004-04-30 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド フルバスタチンナトリウムの結晶形
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
ES2304140T3 (es) * 2001-08-03 2008-09-16 Ciba Holding Inc. Formas cristalinas de sodio de fluvastatina.
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE10316087A1 (de) * 2003-04-08 2004-11-11 Ratiopharm Gmbh Polymorphstabilisierung von Fluvastatin-Natrium in Pharmazeutischen Formulierungen
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
EP1790634A3 (en) * 2003-06-18 2007-06-13 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal form and processes for preparing it
US7368581B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
WO2006008656A2 (en) * 2004-07-21 2006-01-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Oatp-c gene c463a polymorphism underlies variable response of statin therapy
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
WO2006038219A1 (en) * 2004-10-05 2006-04-13 Biocon Limited Process for the preparation of amorphous fluvastatin sodium
WO2006085338A2 (en) * 2005-02-11 2006-08-17 Jubilant Organosys Limited Novel polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
KR20080005230A (ko) * 2006-02-27 2008-01-10 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 신규 형태 및 이의 제조 방법
ATE431818T1 (de) 2006-04-20 2009-06-15 Italiana Sint Spa Verfahren zur herstellung von fluvastatin-natrium
CN101250153B (zh) * 2008-02-26 2013-09-18 深圳信立泰药业股份有限公司 一种制备氟伐他汀钠晶型的工艺
PT2419407E (pt) * 2009-04-15 2013-01-28 Pharmathen Sa Processo melhorado para a preparação de fluvastatina e dos seus sais
CN114280181B (zh) * 2021-12-23 2024-06-18 浙江海翔川南药业有限公司 一种瑞舒伐他汀中间体及其有关物质的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them

Also Published As

Publication number Publication date
CY2461B1 (en) 2005-06-03
DK0907639T3 (da) 2003-06-23
JP4282092B2 (ja) 2009-06-17
PT907639E (pt) 2003-06-30
JP2009149654A (ja) 2009-07-09
DE69719755D1 (de) 2003-04-17
WO1997049681A1 (en) 1997-12-31
US6124340A (en) 2000-09-26
EP0907639B1 (en) 2003-03-12
EP0907639A1 (en) 1999-04-14
AU3366297A (en) 1998-01-14
JP2000512992A (ja) 2000-10-03
ES2194202T3 (es) 2003-11-16
ATE234282T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
US6124340A (en) Polymorphic compounds
US5488150A (en) Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them
DE3881249T2 (de) Fettsaeureamide als acyl-coa-inhibitoren: cholesterolacyltransferase.
DE29724281U1 (de) 4-Phenylpiperidin-Verbindungen
DE10339862A1 (de) 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE19918588A1 (de) Piperidinverbindung
DE202007019460U1 (de) Kristalline Tigecyclin-Formen
DE112012004944T5 (de) Kristalline Formen von Cabazitaxel und deren Herstellungsverfahren
EP0550895B1 (de) 4,13-Dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE60131416T2 (de) Chirale fluochinolon-argininsalzformen
DE69811500T2 (de) Kristallmodifikation von 1-(2,6-difluorbenzyl)-1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum
LU84657A1 (de) Neue kristallmodifikationen,verfahren zu deren herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen
DE69510999T2 (de) Terazosinmonohydrochlorid und Verfahren und Zwischenprodukte für seine Herstellung
DE69917282T2 (de) Verfahren zur herstellung von zofenopril-calciumsalz
DE3443065A1 (de) Kristallines cephalexinhydrochloridmonohydrat, verfahren zu seiner herstellung und seine verwendung
DE69706562T2 (de) N-(4-acetyl-1-piperazinyl)-4-fluorobenzamidhydrat
AT403162B (de) Neue kristallform von morphin-6-glucuronid
DE3789264T2 (de) Beta-lactam-antibiotika.
DE69801163T2 (de) Pseudopolymorphische formen des 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]essigsäure dihydrochlorids
DE69600565T2 (de) Kristaliner Polymorph von Terazosin und dies enthaltende pharmazeutische Zusammensetzungen
DE2513136C3 (de) N-(1-Benzylpiperid-4-yl)-benzamide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
DE69718216T2 (de) Polymorphe von donepezyl-hydrochlorid und verfahren zur herstellung
EP0849265A1 (de) Neue polymorphe Form von Doxazosin-Mesylat (Form II)
CN110804080B (zh) 乙酰氨基阿维菌素晶型a、晶型b、非晶体及其制备方法
DE69617027T2 (de) Polymorphs von prodrug 6-n(l-ala-l-ala)-trovafloxacin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN